https://doi.org/10.1051/epjconf/202430910020
Intracellular delivery, imaging and drug-sensing using a plasmonic-enhanced hybrid nanostystem
1 National Research Council, Institute for Experimental Endocrinology and Oncology “G. Salvatore”, Second Unit, Naples 80131, Italy
2 National Research Council, Institute of Genetics and Biophysics, Naples 80131, Italy
3 National Research Council, Institute of Applied Sciences and Intelligent Systems, Unit of Naples, Naples 80131, Italy
* Corresponding author: Ilaria Rea: ilaria.rea@na.isasi.cnr.it Anna Chiara De Luca: annachiara.deluca@cnr.it Enza Lonardo: enza.lonardo@igb.cnr.it
Published online: 31 October 2024
Metastasis stands as the leading cause of mortality among colorectal cancer (CRC) patients. Galunisertib (LY2157299, LY) is a small molecule demonstrating promising anti-cancer effects by targeting the Transforming Growth Factor-beta (TGF-β) pathway. This route plays a pivotal role in initiating the epithelial-to-mesenchymal transition (EMT), a critical process for metastatic spread. Unfortunately, LY chronic treatment causes undesired effects. To mitigate these side effects, nanoscale drug delivery systems have emerged as a transformative approach in cancer treatment, enhancing drug effectiveness while minimizing toxicity. In this study, we introduce a hybrid nanosystem (DNP-AuNPs-LY@Gel) comprising porous diatomite nanoparticles decorated with plasmonic gold nanoparticles (AuNPs), encapsulating LY within a gelatin shell. This multifunctional nanosystem demonstrates efficient LY delivery, EMT reversal in CRC 2D and 3D cultures, and anti-cancer effects in vivo. Moreover, the nanosystem allowed the quantification with sub-femtogram resolution of the drug intracellularly released using surface-enhanced Raman spectroscopy (SERS). The release of LY is triggered by CRC cell acidic microenviroment. Real-time monitoring of drug release at the single-cell level is achieved by analyzing SERS signals of LY within CRC cells. The heightened efficacy of LY delivery through the DNP-AuNPs-LY@Gel complex offers a promising alternative strategy for reducing drug dosages and subsequent undesired effects.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
